共 50 条
- [41] SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancerCANCER RESEARCH, 2017, 77Rugo, H. S.Pegram, M. D.Gradishar, W. J.Cortes, J.Curigliano, G.Hong, S.Wigginton, J. M.Lechleider, R. J.Cardoso, F.
- [42] A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind TrialONCOLOGIST, 2016, 21 (07): : 789 - 794Blackwell, KimberlyDonskih, RomanJones, C. MichaelNixon, AllenVidal, Maria J.Nakov, RoumenSingh, PritibhaSchaffar, GregorGascon, PereHarbeck, Nadia
- [43] A pilot study of single pegfilgrastim compared with intermittent every other days of 5 shot-filgrastim in breast cancer patients receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy (G-CSF 105 trial: NCT02685111)ANNALS OF ONCOLOGY, 2018, 29 : 5 - 5Jeong, J.Sohn, B. S.Ahn, J-H.Jung, K. H.Kim, J. E.Oh, J.Lee, H.Sohn, J. H.Koh, S-J.Seo, J. H.Lee, K. S.Kim, S-B.
- [44] TRYbeCA-2: A randomized phase 2/3 study of eryaspase in combination with gemcitabine and carboplatin chemotherapy versus chemotherapy alone as first-line treatment in patients with metastatic or locally recurrent triple-negative breast cancer (NCT03674242)CANCER RESEARCH, 2020, 80 (04)Awada, AhmadCortes, JavierSlater, SarahMacPherson, IainCsoszi, TiborBertrand, Jean-BaptisteClermont, Anne-SophiePollard, RachelChrestia-Blanchine, RomainBiswas-Baldwin, NigelYoussoufian, HagopEl-Hariry, Iman
- [45] Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)CANCER RESEARCH, 2016, 76Schwartzberg, L.Vacirca, J. L.Hager, S. J.Adoo, C. S.Ibrahim, E. N.Bhat, G.Choi, M. R.Allen, L. F.Tedesco, K. L.Agajanian, R.
- [46] REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancerCANCER RESEARCH, 2024, 84 (09)Terry NgZhang, YuxinStober, CarolShamess, JenniferMills, NatalieNicholls, StuartIbrahim, MohammedDavoudpour, DanielArmiento, ChristopherSavard, Marie-FranceRushton, MoiraAwan, ArifSehdev, SandeepHilton, JohnSong, XinniGoel, RakeshMacdonald, FionaDaigle, KellyVandermeer, LisaTaljaard, MonicaClemons, Mark
- [47] Chemotherapy dose delays and dose reductions in breast cancer patients receiving dose-dense FEC and docetaxel -: results of a randomized, open-label phase II studyBREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S150 - S150Wildiers, H.Dirix, L.Neven, P.Prove, A.Clement, P.Amant, F.Skacel, T.Paridaens, R.
- [48] A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard ChemotherapyJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) : 1197 - +Leyland-Jones, BrianBondarenko, IgorNemsadze, GiaSmirnov, VitaliyLitvin, IrynaKokhreidze, IrakliAbshilava, LiaJanjalia, MikheilLi, RubiLakshmaiah, Kuntegowda C.Samkharadze, BekaTarasova, OksanaMohapatra, Ranjan KumarSparyk, YaroslavPolenkov, SergeyVladimirov, VladimirXiu, LiangZhu, EugeneKimelblatt, BruceDeprince, KrisSafonov, IlyaBowers, PeterVercammen, Els
- [49] Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGainCANCER RESEARCH, 2022, 82 (04)Andreu-Ballester, Juan CarlosPerez-Garcia, Jose ManuelBermejo, BegonaCaranana, VicenteIranzo, VegaGavila, JoaquinSantaballa, AnaGomez-Soler, Maria CarmenSampayo-Cordero, MiguelMalfettone, AndreaCortes, JavierLlombart-Cussac, Antonio
- [50] Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancerCANCER SCIENCE, 2017, 108 (05): : 987 - 994Tamura, KenjiInoue, KenichiMasuda, NorikazuTakao, ShintaroKashiwaba, MasahiroTokuda, YutakaIwata, HirojiYamamoto, NaohitoAogi, KenjiroSaeki, ToshiakiNakayama, TakahiroSato, NobuakiToyama, TatsuyaIshida, TakanoriArioka, HitoshiSaito, MitsueOhno, ShinjiYamauchi, HidekoYamada, KimitoWatanabe, JunichiroIshiguro, HiroshiFujiwara, Yasuhiro